Alotaibi Sarah A, Alrukban Noura A, Alanizy Layla N, Saleh Ahmad, Alsfouk Bshra A
Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.
Pharmacy Services Administration, King Fahad Medical City, P.O. Box 59046, Riyadh 11525, Saudi Arabia.
J Clin Med. 2024 Dec 23;13(24):7844. doi: 10.3390/jcm13247844.
The objective was to develop and validate a multidimensional scale that measures adherence levels to antiseizure medications and detects patients' reasons for non-adherence. A new scale was developed, namely the "Adherence Scale for Anti-Seizure Medication(s)-10 items [ASASM-10]". It consists of ten statements that cover different causes of non-adherence to antiseizure medications. The domain selection was based on a comprehensive literature review. Guidelines for constructing an effective scale were followed to write the statements. Three independent expert judges assessed the content validity of the scale. The reliability of ASASM-10 was tested using three methods: internal consistency measurement (Cronbach's alpha), Intraclass Correlation Coefficient [ICC] with a 95% Confidence Interval [95% CI], and test-retest reliability. Validity was tested using Principal Component Analysis [PCA] and a correlation coefficient. PCA was applied after measuring sampling adequacy via Kaiser-Meyer-Olkin [KMO] and Bartlett's sphericity. The Medication Adherence Rating Scale [MARS] was selected as a pre-existing self-report method for validation of this new scale. A total of 162 patients completed the study scales (mean ages ± SD: 34.07 ± 10.406 years). The scale demonstrated a good internal consistency with Cronbach's alpha coefficient of 0.80 and exceeded the required value (i.e., 0.70) for the reliability of new scales. ASASM-10 showed a satisfactory ICC (95% CI) of 0.799 (0.718-0.857), -value < 0.001. The test-retest reliability demonstrated a good correlation of ρ = 0.648, -value < 0.001. The construct validity assessed by PCA retained four components as their eigenvalues exceeded one. The correlation coefficient demonstrated a positive moderate correlation between ASASM-10 and MARS (ρ = 0.283), -value < 0.001. The present analyses provided evidence that ASASM-10 is a reliable and valid scale for evaluating patients' adherence to antiseizure medications. It is the first available scale for assessing medication adherence in patients with epilepsy that can be utilized in clinical practice and research settings.
目的是开发并验证一种多维量表，用于衡量抗癫痫药物的依从性水平，并检测患者不依从的原因。开发了一种新的量表，即“抗癫痫药物依从性量表 - 10项[ASASM - 10]”。它由十条陈述组成，涵盖了不依从抗癫痫药物的不同原因。领域选择基于全面的文献综述。遵循构建有效量表的指南来撰写陈述。三位独立的专家评委评估了该量表的内容效度。使用三种方法测试了ASASM - 10的信度：内部一致性测量（克朗巴哈α系数）、组内相关系数[ICC]及95%置信区间[95%CI]，以及重测信度。使用主成分分析[PCA]和相关系数测试效度。在通过凯泽 - 迈耶 - 奥尔金[KMO]和巴特利特球形度测量抽样充分性后应用PCA。选择药物依从性评定量表[MARS]作为一种现有的自我报告方法来验证这个新量表。共有162名患者完成了研究量表（平均年龄±标准差：34.07±10.406岁）。该量表显示出良好的内部一致性，克朗巴哈α系数为0.80，超过了新量表信度所需的值（即0.70）。ASASM - 10显示出令人满意的ICC（95%CI）为0.799（0.718 - 0.857），P值<0.001。重测信度显示出良好的相关性，ρ = 0.648，P值<0.001。通过PCA评估的结构效度保留了四个成分，因为它们的特征值超过了1。相关系数显示ASASM - 10与MARS之间存在中度正相关（ρ = 0.283），P值<0.001。目前的分析提供了证据，表明ASASM - 10是一种可靠且有效的量表，用于评估患者对抗癫痫药物的依从性。它是首个可用于临床实践和研究环境中评估癫痫患者药物依从性的量表。
